Lineage Cell Therapeutics (LCTX) Research & Development (2010 - 2026)

Lineage Cell Therapeutics has reported Research & Development for 17 years, with the latest figure at $4.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development rose 35.97% year-over-year to $4.2 million; the trailing twelve-month figure through Mar 2026 stood at $18.8 million (up 49.88% YoY), and the FY2025 full-year result was $17.7 million, up 42.15% from the prior year.
• Research & Development for Q1 2026 stood at $4.2 million, down from $8.2 million in the prior quarter.
• The five-year high for Research & Development was $8.2 million in Q4 2025, with the low at $2.9 million in Q2 2024.
• Historically, Research & Development has averaged $3.8 million across 5 years, with a median of $3.4 million in 2024.
• Annual changes were most pronounced in 2022 — Research & Development plunged 83.44% — and 2025, when it soared 140.67%.
• Lineage Cell Therapeutics' Research & Development stood at $4.1 million in 2022, then retreated by 4.82% to $3.9 million in 2023, then fell by 12.37% to $3.4 million in 2024, then soared by 140.67% to $8.2 million in 2025, then slumped by 48.6% to $4.2 million in 2026.
• The last three Research & Development figures came in at $4.2 million (Q1 2026), $8.2 million (Q4 2025), and $3.3 million (Q3 2025), per Business Quant data.